The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis

Table 5 OS and TNTD among nab-paclitaxel initiators by line of therapy and treatment regimen^a,b

Variable	Total no.	OS			TNTD
Variable	Total no.	Events	Median, mo	95 % CI	Events	Median, mo	95 % CI
Overall	664	305	17.4	(16.1–19.0)	491	6.1	(5.6–6.7)
Monotherapy	405	184	16.8	(14.5–18.5)	293	5.8	(5.0–6.7)
Combination therapy	259	121	18.7	(15.9–24.0)	198	6.5	(5.8–7.8)
First line	172	68	22.7	(18.6–34.3)	127	7.1	(6.2–9.0)
Monotherapy	109	37	20.8	(16.5–39.2)	76	6.7	(5.0–7.4)
Combination therapy	63	31	23.0	(18.7–37.3)	51	8.5	(6.5–13.1)
Second line	211	99	17.4	(14.1–22.3)	151	6.6	(5.3–8.1)
Monotherapy	129	67	15.6	(12.8–21.4)	97	5.8	(4.7–7.9)
Combination therapy^c	82	32	>18.7	–	54	7.3	(5.1–9.7)
Third or later line	281	138	15.1	(12.7–16.9)	213	5.3	(4.6–6.0)
Monotherapy	167	80	15.6	(11.6–17.8)	120	5.3	(4.2–6.1)
Combination therapy	114	58	14.3	(11.9–17.4)	93	5.5	(4.6–6.4)

OS overall survival, TNTD time to next therapy or death
^aData are from the Optum Research Database, January 1, 2005 to September 30, 2012
^bFollow-up time was calculated from index date until disenrollment from the health plan, death (or treatment discontinuation), or the end of the study period (September 30, 2012)
^cThe 95 % CI of median survival time is missing because more than half of the patients survived during the study period

ISSN: 1471-2407